Lipid Metabolism, Lipogenesis, and Resistance to Third Generation EGFR‐TKIs
Journal of Clinical Laboratory Analysis · 2026-07 · 40 (13)
DOI: 10.1002/jcla.70274 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 03.06.2026. Verfasst von Wenhao Luo und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Lipid Metabolism, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Lipogenesis. Die Arbeit nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Project of Sichuan Provincial Health Commission, Wu Jieping Medical Foundation, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
Background
Cancer metabolism has emerged as a critical area of study in cancer research. Dysregulated lipid metabolism has been observed in various cancer types, and this metabolic rewiring facilitates tumor growth, metastasis, and treatment resistance. Additionally, aberrant lipid metabolism is associated with poor patient prognosis.
Methods
This review aims to provide a comprehensive overview of cancer metabolism, with a specific focus on lipid metabolism/lipogenesis and its association with resistance to third‐generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs).
Results
Lipid metabolism/lipogenesis provides cancer cells with energy substrates and building blocks for membrane biogenesis. In parallel, resistance to third‐generation EGFR‐TKIs has emerged as a major challenge in the treatment of non‐small cell lung cancer (NSCLC) driven by EGFR mutations.
Conclusion
Understanding the intricate connections between lipid metabolism/lipogenesis and resistance to third‐generation EGFR‐TKIs is crucial for developing effective therapeutic strategies. Targeting lipid metabolism pathways holds promise as a novel therapeutic approach to overcome treatment resistance and improve patient prognosis. Further research is needed to better understand the underlying mechanisms and identify potential drug targets in lipid metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
- West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China.
- Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
- Lung Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
- Department of Thoracic Surgery, The First Affliliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
- Department of Thoracic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
ORCID-Profile: Wang Shen
Förderung
- Science and Technology Project of Sichuan Provincial Health Commission
- Wu Jieping Medical Foundation
- Natural Science Foundation of Sichuan Province
Zitieren
APA
Luo, W., Wang, Z., Ma, G., Shen, W., Chen, X., & Liao, Y. (2026). Lipid Metabolism, Lipogenesis, and Resistance to Third Generation EGFR‐TKIs. Journal of Clinical Laboratory Analysis, 40(13). https://doi.org/10.1002/jcla.70274
Vancouver
Luo W, Wang Z, Ma G, Shen W, Chen X, Liao Y. Lipid Metabolism, Lipogenesis, and Resistance to Third Generation EGFR‐TKIs. Journal of Clinical Laboratory Analysis. 2026;40(13). doi:10.1002/jcla.70274
BibTeX
@article{Luo2026,
author = {Luo, Wenhao and Wang, Zun and Ma, Guangzhi and Shen, Wang and Chen, Xiaobo and Liao, Yida},
title = {Lipid Metabolism, Lipogenesis, and Resistance to Third Generation EGFR‐TKIs},
journal = {Journal of Clinical Laboratory Analysis},
year = {2026},
volume = {40},
number = {13},
doi = {10.1002/jcla.70274}
}
EUVIMED